Document is current
Any future updates will be listed below
-
Authors
Stur, Elaine
Peng, Fuduan
Teng, Pang-ning https://orcid.org/0000-0002-7919-3567
Bayraktar, Emine
Hu, Min
Corvigno, Sara https://orcid.org/0000-0001-5458-2243
Brown, David J.
Lee, Sanghoon
Moore, Kathleen N.
Bateman, Nicholas W. https://orcid.org/0000-0002-4425-9511
Darcy, Kathleen M. https://orcid.org/0000-0003-2888-2968
Maxwell, George L.
P. Conrads, Thomas https://orcid.org/0000-0003-4742-3281
Sahni, Nidhi
Vázquez-García, Ignacio
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
Celestino, Joseph
D. Fleming, Nicole
Navin, Nicholas E. https://orcid.org/0000-0002-2106-8624
Wang, Linghua
Sood, Anil K. https://orcid.org/0000-0003-4242-1762
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 17 January 2025
First Online: 25 April 2025
Competing interests
: A.K.S. is a consultant for Merck, GSK, Astra Zeneca, ImmunoGen, Iylon, Onxeo and DSMB for Advenchen and Mural Oncology. N.D.F. is a consultant for GlaxoSmithKline and Immunogen. S.P.S. reports research funding from AstraZeneca and Bristol Myers Squibb, outside the scope of this work; S.P.S. is a consultant and shareholder of Canexia Health Inc. The other authors declare no competing interests.
